Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Mai 2026 08:05 ET | Quelle: WW International Inc.

Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it will begin offering...
28. April 2026 16:01 ET | Quelle: PMGC Holdings Inc.

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate
21. April 2026 10:30 ET | Quelle: GLP Diet

GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews

GLP Diet App supports GLP-1 users (Ozempic, Mounjaro) with meal plans, 5-min workouts & progress tracking. 2,700+ reviews.
15. April 2026 15:19 ET | Quelle: King Faisal Prize

Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates

Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) -- On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal Foundation, and King Faisal...
13. April 2026 07:30 ET | Quelle: PMGC Holdings Inc.

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting
30. März 2026 07:03 ET | Quelle: PMGC Holdings Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
27. März 2026 16:05 ET | Quelle: PMGC Holdings Inc.

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
10. März 2026 10:00 ET | Quelle: GLP Diet

GLP Diet Review: A Personalized App Designed to Support GLP-1 Weight Loss Journeys

GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.
10. März 2026 07:30 ET | Quelle: PMGC Holdings Inc.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
09. Februar 2026 06:59 ET | Quelle: Novo Nordisk A/S

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.

Nächste Seite